Company intelligence / Profile preview

CorInnova

Houston, Texas, United Statescorinnova.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CorInnova’s preclinical studies have demonstrated that their minimally invasive soft robotic cardiac assist device can increase cardiac output by up to 50% in animal models of acute heart failure. The technology aims to provide short-term mechanical circulatory support without blood contact, reducing risks such as thrombosis and stroke associated with current devices. No human clinical results are available yet; first-in-human studies are in planning stages.

Therapeutic areas: Cardiovascular
Modalities: DeviceSoft robotic cardiac assist device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Cardiacstar

Pre-clinical

Indications: Acute heart failure

Partnerships

Johnson & Johnson Innovation JLABS @ TMC residency/program participant

Beyond the preview

Go deeper on CorInnova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorInnova.

Explore the full profile